{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:32:30Z","timestamp":1778005950140,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41429-022-00592-w","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T08:02:59Z","timestamp":1674460979000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of surfactants and other body fluids on in vitro activity of a novel \u03b2-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae"],"prefix":"10.1038","volume":"76","author":[{"given":"Alina","family":"Nussbaumer-Pr\u00f6ll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Belley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly K.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"592_CR1","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis. 2005;191:2149\u201352.","journal-title":"J Infect Dis"},{"key":"592_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.00875-07","volume":"52","author":"MH Gotfried","year":"2008","unstructured":"Gotfried MH, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008;52:92\u201397.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/AAC.39.2.329","volume":"39","author":"A Van\u2019t Veen","year":"1995","unstructured":"Van\u2019t Veen A, Mouton JW, Gommers D, Kluytmans JANAJW, Dekkers P. Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother. 1995;39:329\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR4","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AAC.00322-11","volume":"55","author":"D Dugourd","year":"2011","unstructured":"Dugourd D, et al. Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant. Antimicrob Agents Chemother. 2011;55:3720\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR5","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1128\/AAC.00778-13","volume":"57","author":"R Schwameis","year":"2013","unstructured":"Schwameis R, et al. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother. 2013;57:5151\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12080773","volume":"12","author":"A Nussbaumer-Pr\u00f6ll","year":"2020","unstructured":"Nussbaumer-Pr\u00f6ll A, Zeitlinger M. Use of supplemented or human material to simulate pd behavior of antibiotics at the target site in vitro. Pharmaceutics. 2020;12:1\u201318.","journal-title":"Pharmaceutics"},{"key":"592_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, et al. Ceftolozane\/tazobactam: A novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31\u201351.","journal-title":"Drugs"},{"key":"592_CR8","first-page":"1","volume":"63","author":"M Ian","year":"2019","unstructured":"Ian M, Sophie M, Stephen H, Stuart S, Philipp K. In vitro activity of cefepime-enmetazobactam against gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015. Antimicrob Agents Chemother. 2019;63:1\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00105-19","volume":"63","author":"KM Papp-wallace","year":"2019","unstructured":"Papp-wallace KM, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination. Antimicrob Agents Chemother. 2019;63:1\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"592_CR10","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. (2019). Available at: https:\/\/clsi.org\/standards\/products\/iso-documents\/iso-20776-12006\/."},{"key":"592_CR11","doi-asserted-by":"crossref","unstructured":"Das S, et al. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: Towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother. 2021;65:e01468-20.","DOI":"10.1128\/AAC.01468-20"},{"key":"592_CR12","doi-asserted-by":"crossref","unstructured":"Johnson, A et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-beta-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-Producing Klebsiella pneumoniae. 2020;64:1\u201314.","DOI":"10.1128\/AAC.00180-20"},{"key":"592_CR13","first-page":"1","volume":"dkz488","author":"AK Nussbaumer-Pr\u00f6ll","year":"2019","unstructured":"Nussbaumer-Pr\u00f6ll AK, et al. Low pH reduces the activity of ceftolozane \/ tazobactam in human urine, but confirms current breakpoints for urinary tract infections. J Antimicrob Chemother. 2019;dkz488:1\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"592_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diagmicrobio.2017.08.011","volume":"89","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Duncan LR, Rhomberg PR, Sader HS. Enhanced activity of cefepime\u2013tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. Diagn Microbiol Infect Dis. 2017;89:305\u20139.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00592-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00592-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:05:32Z","timestamp":1677456332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-022-00592-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1038\/s41429-022-00592-w","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}